<\/p>\n
THE LANCET \u2022 Vol 351 \u2022 February 21, 1998 <\/span>541<\/span><\/p>\n \u00a0<\/span><\/p>\n Oral antifungal agents for Onychomycosis affects about American population.<\/span>1 <\/span>It is commonly more than a<\/span><\/p>\n cosmetic issue since it can affect mobility as well as An important advance in its development of oral their administration.<\/span><\/p>\n \u00a0<\/span><\/p>\n \u2026<\/span><\/p>\n \u00a0<\/span><\/p>\n The newer generation treatment of and fluconazole. approved for the continuous regimen pulse therapy was reaches the distal starting therapy 9\u201312 months from present at low to within 7\u201314 days Itraconazole pulse onychomycosis in latest of the onychomycosis is \u00a0<\/span><\/p>\n Terbinafine, plate via both the itraconazole,terbinafine the distal end of of therapy and withdrawal of the plasma within difference is The persistence of the mycological agents are higher pharmacokinetics shortening of compliance. griseofulvin, only, the newer Candida <\/span>species and some non-dermatophyte moulds.<\/span><\/p>\n Pharmacoeconomic and itraconazole onychomycosis of pulse therapy with treatments, with \u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n For terbinafine for onychomycosis In a double-blind compared with 12 proximal part of the patients who cure rate at 48 week group was 56% (46\/56) for the from involvement. A observed in those with infection of Positive mycology failure or relapse investigators<\/span>14 <\/span>suggest that one would be to check start of therapy with positive \u00a0<\/span><\/p>\n With itraconazole, therapy, there has pulse (200 mg months) against months). At month mycological cure \u00a0<\/span>(n=59) and 66% for continuous therapy (n=62). patients with less mycological cure therapy and 79% than 75% of the corresponding figures Although there investigators over the onychomycosis of requires exactly regimen, thus \u00a0<\/span><\/p>\n The newer oral antifungal some cases in conjunction surgery, are providing the onychomycosis of the toes in affected individuals. unikely to respond to therapy efforts to do so and to find manner of treating pedal onychomycosis Recurrence of disease still patients. It can be due to onychomycosis or reinfection. obtained it is prudent to measures that will reduce the Some strategies include high level of dermatophyte swimming pools, showers, old shoes that may have a and the judicious use of \u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n Aditya K Gupta, Division of Dermatology, Department of Medicine, Sunnybrook Science Center, University of Toronto, Ontario, Canada;<\/span><\/p>\n
\nonychomycosis<\/span><\/p>\n
\n7\u20138% of the North<\/span><\/p>\n
\ncause pain or discomfort and<\/span><\/p>\n
\nother activities of daily living.<\/span>2<\/span><\/p>\n
\nmanagement is the<\/span><\/p>\n
\nantifungal agents and methods of<\/span><\/p>\n
\nof oral antifungal agents for the<\/span><\/p>\n
\nonychomycosis are terbinafine,<\/span>8 <\/span>itraconazole,<\/span><\/p>\n
\nItraconazole, a triazole, was first<\/span><\/p>\n
\ntreatment of onychomycosis as a<\/span><\/p>\n
\nin Mexico in 1989.<\/span>9 <\/span>The concept of<\/span><\/p>\n
\nsoon introduced, because itraconazole<\/span><\/p>\n
\nend of the toenail within 2 weeks of<\/span><\/p>\n
\nand persists in the nail plate for about<\/span><\/p>\n
\nthe start of therapy, even though it is<\/span><\/p>\n
\nnegligible concentrations in the plasma<\/span><\/p>\n
\nafter the end of a week of treatment.<\/span>9,10<\/span><\/p>\n
\ntherapy was first approved for<\/span><\/p>\n
\n1993, in Finland. Fluconazole, the<\/span><\/p>\n
\nnewer antifungal agents for the treatment of<\/span><\/p>\n
\nalso a triazole.<\/span><\/p>\n
\nitraconazole, and fluconazole enter the nail<\/span><\/p>\n
\nnail matrix and nail bed. Like<\/span><\/p>\n
\nand fluconazole can be found at<\/span><\/p>\n
\nthe nail plate within a few weeks of start<\/span><\/p>\n
\npersist in the nail for several months after<\/span><\/p>\n
\ntherapy.<\/span>11-13 <\/span>They are also eliminated from<\/span><\/p>\n
\nweeks of the end of treatment. This<\/span><\/p>\n
\nassociated with a high benefit to risk ratio.<\/span><\/p>\n
\ndrug in the nail plate may explain why<\/span><\/p>\n
\ncure rates (60\u201380%) for the newer<\/span><\/p>\n
\nthan that of griseofulvin.<\/span>6 <\/span>The<\/span><\/p>\n
\nof these newer agents has enabled<\/span><\/p>\n
\ntreatment duration, which increases<\/span><\/p>\n
\nAnother advantage is that, unlike<\/span><\/p>\n
\nwhich has activity against dermatophytes<\/span><\/p>\n
\nagents are also active in vivo against<\/span><\/p>\n
\nanalyses of griseofulvin, terbinafine,<\/span><\/p>\n
\n(continuous or pulse) in the treatment of<\/span><\/p>\n
\nthe toes indicate that terbinafine and<\/span><\/p>\n
\nitraconazole are the two most costeffective<\/span><\/p>\n
\nno significant difference between them.<\/span>6<\/span><\/p>\n
\nthe recommended treatment regimen<\/span><\/p>\n
\nof the toes is 250 mg\/day for 12 weeks.<\/span><\/p>\n
\ntrial 6 weeks of treatment was<\/span><\/p>\n
\nweeks in patients in whom the<\/span><\/p>\n
\nthe toenails was not affected.<\/span>14 <\/span>Among<\/span><\/p>\n
\ncompleted the study, the mycological<\/span><\/p>\n
\nweeks after the start of therapy in the 6-<\/span><\/p>\n
\n(34\/61), compared with 82%<\/span><\/p>\n
\n12-week group. Responders did not differ<\/span><\/p>\n
\nnon-responders in age, weight, or degree of nail<\/span><\/p>\n
\ntrend towards better response was<\/span><\/p>\n
\nwith a short duration of disease and<\/span><\/p>\n
\ntoenails other than the big (first) toenail.<\/span><\/p>\n
\nat week 24 predicted therapeutic<\/span><\/p>\n
\nin 68% (25\/37) patients. The<\/span><\/p>\n
\nmanagement approach<\/span><\/p>\n
\nmycological status 6 months after the<\/span><\/p>\n
\nand then to repeat treatment for those<\/span><\/p>\n
\nresults.<\/span><\/p>\n
\ndespite the popularity of pulse<\/span><\/p>\n
\nbeen only one study that has compared<\/span><\/p>\n
\ntwice daily for 1 week a month for 3<\/span><\/p>\n
\ncontinuous therapy (200 mg daily for 3<\/span><\/p>\n
\n12 after the start of therapy,<\/span><\/p>\n
\nrates were 69% for pulse therapy<\/span><\/p>\n
\nIn<\/span><\/p>\n
\nthan 75% nail-plate involvement, the<\/span><\/p>\n
\nrates at month 12 were 75% for pulse<\/span><\/p>\n
\nfor continuous therapy. When more<\/span><\/p>\n
\nnail plate was affected, the<\/span><\/p>\n
\nwere 66% and 60%, respectively.<\/span>15<\/span><\/p>\n
\nwere no significant differences, the<\/span><\/p>\n
\nfound a trend for superiority of the pulse<\/span><\/p>\n
\ncontinuous regimen. Furthermore, for<\/span><\/p>\n
\nthe toes, itraconazole pulse therapy<\/span><\/p>\n
\nhalf the drug needed for the continuous<\/span><\/p>\n
\nmaking the former more cost-effective.<\/span><\/p>\n
\nagents used alone, or in<\/span><\/p>\n
\nwith topical antifungals or<\/span><\/p>\n
\nbasis for effective treatment of<\/span><\/p>\n
\na large proportion of<\/span><\/p>\n
\nEfficacy can be improved if those<\/span><\/p>\n
\ncan be identified, and<\/span><\/p>\n
\nthe most cost-effective<\/span><\/p>\n
\nare under way.<\/span><\/p>\n
\noccurs in a high proportion of<\/span><\/p>\n
\ninadequate eradication of<\/span><\/p>\n
\nHence once cure has been<\/span><\/p>\n
\ncounsel the patient about<\/span><\/p>\n
\nlikelihood of reinfection.<\/span>16<\/span><\/p>\n
\navoidance of facilities with a<\/span><\/p>\n
\ncontamination (communal<\/span><\/p>\n
\nchanging facilities) discarding<\/span><\/p>\n
\nhigh density of fungal spores,<\/span><\/p>\n
\ntopical antifungal agents.<\/span><\/p>\n
\n*Richard K Scher<\/span><\/p>\n
\nHealth<\/span><\/p>\n